GLP-1s and PCOS weight loss: what the evidence actually says

What's this video probably claiming?

Based on the caption and hashtag stack, @lizdamyl is almost certainly sharing a personal weight loss transformation tied to GLP-1 receptor agonist use, framed through the lens of PCOS as the underlying barrier she couldn't overcome through other means. The #ivimaffiliate tag confirms this is sponsored content for Iвим Health, a telehealth platform prescribing compounded semaglutide. The narrative arc is familiar: years of failed attempts, PCOS as the villain, GLP-1 as the solution. She's likely describing reduced appetite, meaningful weight loss, and possibly improvements in cycle regularity or energy. The "free consultation" CTA in the bio converts the emotional story into a lead-generation funnel. None of that is inherently wrong, but the framing of GLP-1s as a PCOS-specific fix deserves a harder look than a 60-second TikTok typically provides.

What does the science actually show?

The evidence for GLP-1 receptor agonists in PCOS is genuinely promising but still developing. A 2023 randomized controlled trial by Jensterle et al. published in Diabetes, Obesity and Metabolism found that semaglutide 1.0mg weekly produced significantly greater weight reduction than liraglutide 1.2mg in women with PCOS and obesity, with participants losing around 9% of body weight over 24 weeks. A 2022 meta-analysis by Xu et al. in Frontiers in Endocrinology found GLP-1 agonists improved menstrual regularity and reduced testosterone levels alongside weight loss in PCOS populations. But here's the thing: most of these trials are small, short-duration, and use doses different from what compounded telehealth platforms typically prescribe. The weight loss is real. Calling it a PCOS cure is not supported by the data.

Where does the social media noise diverge from clinical reality?

The gap between TikTok PCOS content and actual endocrinology is wide. First, PCOS is not a single condition. It presents across a spectrum of phenotypes, including some women with minimal androgen excess and others with severe metabolic dysfunction. A GLP-1 response in one phenotype does not predict outcomes across all. Second, the affiliate structure here matters. The #ivimaffiliate tag means this creator is financially incentivized to drive consultations, which is a conflict of interest that should be disclosed more prominently than a buried hashtag. Third, weight loss with semaglutide in PCOS does not reliably persist without continued use. A 2022 withdrawal study by Wilding et al. in Diabetes, Obesity and Metabolism showed participants regained roughly two-thirds of lost weight within a year of stopping the drug. That context is almost never in these videos.

What should you actually know?

GLP-1 receptor agonists are a legitimate and increasingly supported option for women with PCOS who have obesity or insulin resistance as part of their presentation. The mechanism makes sense: reducing insulin levels and body fat can lower androgen production and improve cycle regularity. But a few things need to be said plainly. Compounded semaglutide is not the same product as FDA-approved Wegovy or Ozempic. Purity, potency, and sterility standards differ, and the FDA has raised concerns about compounded versions. Cost and access advantages of compounded products are real, but the trade-offs deserve disclosure. Anyone considering this should have a proper workup for PCOS phenotype, metabolic markers, and contraindications before starting. A TikTok transformation story, however genuine, is not a clinical consultation.